131 related articles for article (PubMed ID: 15771599)
1. Role of bone scintigraphy and tumor marker-Ca 15-3 in detection of bone metastases in patients with breast cancer.
Begić A; Kucukalić-Selimović E; Obralić N; Durić O; Lacević N; Begović S; Dzubur-Aganović M
Bosn J Basic Med Sci; 2005 Feb; 5(1):23-6. PubMed ID: 15771599
[TBL] [Abstract][Full Text] [Related]
2. Correlation between bone scintigraphy and tumor markers in patients with breast carcinoma.
Begić A; Kucukalić-Selimović E; Obralić N; Durić O; Lacević N; Skopljak A
Bosn J Basic Med Sci; 2006 Feb; 6(1):75-7. PubMed ID: 16533185
[TBL] [Abstract][Full Text] [Related]
3. Comparison of bone scintigraphy with serum tumor markers of CA 15-3 and carcinoembryonic antigen in patients with breast carcinoma.
Gedik GK; Kiratli PO; Tascioglu B; Aras T
Saudi Med J; 2006 Mar; 27(3):317-22. PubMed ID: 16532090
[TBL] [Abstract][Full Text] [Related]
4. Single determination of CA 15.3 and bone scintigraphy in the diagnosis of skeletal metastases of breast cancer.
Crippa F; Bombardieri E; Seregni E; Castellani MR; Gasparini M; Maffioli L; Pizzichetta M; Buraggi GL
J Nucl Biol Med (1991); 1992; 36(1):52-5. PubMed ID: 1450226
[TBL] [Abstract][Full Text] [Related]
5. Expressiveness of Bone Markers in Breast Cancer with Bone Metastases.
Zulauf N; Brüggmann D; Groneberg D; Oremek GM
Oncology; 2019; 97(4):236-244. PubMed ID: 31412345
[TBL] [Abstract][Full Text] [Related]
6. Association between bone scintigraphy and serum levels of tumor markers in the detection of bone disease in breast cancer patients.
Zissimopoulos A; Matthaios D; Matthaiou E; Mantadakis E; Karaitianos I
J BUON; 2007; 12(4):505-11. PubMed ID: 18067209
[TBL] [Abstract][Full Text] [Related]
7. The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy.
Nicolini A; Ferrari P; Sagripanti A; Carpi A
Br J Cancer; 1999 Mar; 79(9-10):1443-7. PubMed ID: 10188888
[TBL] [Abstract][Full Text] [Related]
8. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
[TBL] [Abstract][Full Text] [Related]
9. [Reliability of CA 15-3 in the follow up of female patients with breast carcinoma and bone metastases].
del Rocío Estrada-Sánchez G; Mireles Enríquez M; Valverde Castañeda N
Rev Invest Clin; 2003; 55(4):412-8. PubMed ID: 14635605
[TBL] [Abstract][Full Text] [Related]
10. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
Zissimopoulos A; Stellos K; Matthaios D; Petrakis G; Parmenopoulou V; Babatsikou F; Matthaiou E; Theodosiadou E; Hountis P; Koutis C
J BUON; 2009; 14(3):463-72. PubMed ID: 19810140
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of magnetic resonance imaging and scintigraphy in patients with metastatic breast cancer of the axial skeleton: a comparative study.
Yilmaz MH; Ozguroglu M; Mert D; Turna H; Demir G; Adaletli I; Ulus S; Halac M; Kanberoğlu K
Med Oncol; 2008; 25(3):257-63. PubMed ID: 18040900
[TBL] [Abstract][Full Text] [Related]
12. Relationship between bone scintigraphy and tumor markers in patients with breast cancer.
Yildiz M; Oral B; Bozkurt M; Cobaner A
Ann Nucl Med; 2004 Sep; 18(6):501-5. PubMed ID: 15515750
[TBL] [Abstract][Full Text] [Related]
13. Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer.
Hahn S; Heusner T; Kümmel S; Köninger A; Nagarajah J; Müller S; Boy C; Forsting M; Bockisch A; Antoch G; Stahl A
Acta Radiol; 2011 Nov; 52(9):1009-14. PubMed ID: 21969709
[TBL] [Abstract][Full Text] [Related]
14. [Procollagen-I, collagen telopeptide I, CEA, CA 15-3 as compared to bone scintigraphy in patients with breast cancer].
Zissimopoulos A; Petrakis G; Stellos K; Baziotis N
Hell J Nucl Med; 2006; 9(1):60-4. PubMed ID: 16617400
[TBL] [Abstract][Full Text] [Related]
15. Comparison of bone scanning and CA 15-3 serum concentration in the follow-up of breast cancer.
Montravers F; Younsi N; Rousseau C; Philippe C; Seddiki M; Uzan S; Izrael V; Talbot JN
Anticancer Res; 1997; 17(3B):1683-6. PubMed ID: 9179218
[TBL] [Abstract][Full Text] [Related]
16. Comparative detectability of bone metastases and impact on therapy of magnetic resonance imaging and bone scintigraphy in patients with breast cancer.
Altehoefer C; Ghanem N; Högerle S; Moser E; Langer M
Eur J Radiol; 2001 Oct; 40(1):16-23. PubMed ID: 11673003
[TBL] [Abstract][Full Text] [Related]
17. Comparison of whole-body MRI with automatic moving table technique and bone scintigraphy for screening for bone metastases in patients with breast cancer.
Engelhard K; Hollenbach HP; Wohlfart K; von Imhoff E; Fellner FA
Eur Radiol; 2004 Jan; 14(1):99-105. PubMed ID: 12845463
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of bone metastases from breast cancer by bone scintigraphy and positron emission tomography/computed tomography imaging.
Pires AO; Borges US; Lopes-Costa PV; Gebrim LH; da Silva BB
Eur J Obstet Gynecol Reprod Biol; 2014 Sep; 180():138-41. PubMed ID: 25037283
[TBL] [Abstract][Full Text] [Related]
19. CA 15-3 and bone scintigraphy in the follow-up of breast cancer.
Younsi N; Montravers F; Philippe C; Seddiki M; Uzan S; Izrael V; Talbot JN
Int J Biol Markers; 1997; 12(4):154-7. PubMed ID: 9582604
[TBL] [Abstract][Full Text] [Related]
20. Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan?
Caglar M; Kupik O; Karabulut E; Høilund-Carlsen PF
Rev Esp Med Nucl Imagen Mol; 2016; 35(1):3-11. PubMed ID: 26514321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
